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Overlap of primary biliary cirrhosis and primary 
sclerosing cholangitis – a rare coincidence  
or a new syndrome
Background: Overlap syndrome has been introduced to the field of hepatology to describe the 
coexistence of two or more autoimmune hepatic conditions in the same individual. This is a rare 
clinical case of a patient diagnosed with primary biliary cirrhosis (PBC) who later developed 
primary sclerosing cholangitis (PSC). This is a unique case as no other cases with a similar 
pattern have been reported. Overlap syndrome does not include the coexistence of PBC and 
PSC as a distinctive syndrome so far.
Case report: A middle-aged woman suffering from PBC for 17 years got admitted with clinical 
and biochemical features of cholestatic syndrome. A provisional diagnosis of worsening PBC 
was proved wrong by magnetic resonance cholangiopancreatography, which revealed typical 
benign stricture and dilatation of common bile duct with typical beading appearance suggestive 
of PSC. The patient was stented and treated with an increased dose of ursodeoxycholic acid 
(UDCA) which improved the symptoms and the biochemical picture.
Conclusion: This is a clear overlap of PBC–PSC. It is very difficult to say whether it is a rare 
coincidence or a new overlap syndrome, but there are no clear guidelines for management of 
these patients. Currently, the treatment involves endoscopic duct dilatation, UDCA, and regular 
follow-ups to rule out hepato-biliary tumor occurrence.
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Introduction
Primary sclerosing cholangitis (PSC) is a rare cholestatic liver disease with the 
histological features of chronic inflammation and fibrotic obliteration of the hepatic 
biliary tree, resulting in bile stasis and hepatic fibrosis.1 It commonly co-exists with 
autoimmune hepatitis (AIH) as a part of hepatic overlap syndrome. In our case, it 
presents on the background of primary biliary cirrhosis (PBC), another autoimmune 
disorder affecting the hepatobiliary structures.
Case report
A 64-year-old woman with a history of PBC presented with a two-week history 
of obstructive jaundice. PBC was first diagnosed in 1992 when she presented with 
lethargy, pruritus, and deranged liver function tests. At that time she had a normal 
endoscopic retrograde cholangiopancreatography (ERCP) and her antimitochondrial 
antibody (AMA) was negative, but liver biopsy revealed PBC. She was treated with 
ursodeoxycholic acid (UDCA). A repeat biopsy in 1996 revealed similar histological 
appearance (Figure 1) which revealed a portal tract with dense lymphoplasmacytic 
infiltrate and lymphoid aggregate in addition to interlobular bile ducts showing a focal 
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Figure 1 Histopathology periodic acid-schiff staining reveals lymphoplasmacytic and 
lymphoid aggregates and damaged bile ducts (arrows).
rupture of its   cholangiocytic lining at the site of an adjacent 
epithelioid granuloma, and no evidence of any dysplasia. For 
the next seventeen years her baseline alkaline phosphatase, 
bilirubin, and transaminase levels were stable. She was also 
suffering from rheumatoid arthritis for which she was on 
prednisolone and azathioprine.
Current admission was due to two weeks history of jaun-
dice, abdominal pain, loss of appetite, nausea, vomiting, loss 
of weight, fever, pale stools, and dark urine. She never had 
these symptoms with PBC.
On clinical examination she was dry, flushed, febrile, 
icteric, tachycardic, dyspneic, and scratch marks on her skin. 
No other clinical signs of chronic liver disease. Chest was 
clear, and heart sounds were normal and hemodynamically 
stable. Abdominal examination revealed soft abdomen with 
right upper quadrant tenderness and normal bowel sounds. 
No evidence of ascites, splenomegaly, and pedal edema was 
found. Routine laboratory tests revealed normal renal func-
tions, electrolytes, and bone profile, but C-reactive   protein 
was elevated at 335 mg/L. Liver function tests showed 
predominantly cholestatic picture with elevated alkaline 
phospatase at 2,627 IU/L and bilirubin at 377 umol/L, but 
the synthetic function of the liver was within normal range. 
Her full blood count was essentially normal apart from an 
elevated white blood cell count of 160,000/ml secondary to 
neutrophilia. Liver autoimmune screen and tumor marker 
results are listed in Table 1.
An ultrasound scan of the liver and biliary system showed 
heterogeneous liver texture and irregular margins. Both lobes 
of the liver showed intrahepatic duct dilatation. No focal lesion 
was noted. The common bile duct (CBD) was dilated down 
to the pancreas, but no definite obstructive lesion or stone 
was found. Mild pancreatic duct dilatation was also noted. 
Computer tomography imaging (Figure 2) showed similar 
appearances with change in caliber of distal CBD at the 
Table 1 Liver autoimmune and virology screen
AMA M2 negative
smooth muscle antibodies negative
LKM antibodies negative
Gastric parietal cell antibody negative
Anti-nuclear Hep-2 antibodies positive (Weak)
ANCA MPO negative
ANCA PR3 negative
ds – DNA antibodies negative
eNA antibody screen negative
Immunoglobulin IgG4 negative
Hepatitis serology A,B,C negative
Ca 19-9, alpha feto protein, CeA 125 within normal range
Immunoglobulin IgA, IgG, IgM within normal range
pancreatic level. There was no evidence of pancreatic mass or 
stone. No fibrosis or calcification was noted in the pancreas. 
There was a slight concentric wall thickening of the distal duct. 
ERCP imaging (Figure 3) revealed a low benign-looking stric-
ture with intrahepatic dilatation suggestive of PSC and a plastic 
stent was inserted for biliary drainage. To confirm the above 
diagnosis MRCP imaging (Figure 4) showcased dilatation of 
CBD distally measuring up to 1.5 cm tapering at the ampulla. 
The ducts showed significant typical beading appearance 
which would go with presumptive diagnosis of PSC.
The patient was treated with intravenous antibiotics, 
fluids, and a high dose of UDCA. She clinically got better, 
and liver and infection markers settled. The patient was 
discharged with regular follow-up arrangements.
Discussion
Overlap syndrome includes various forms of   autoimmune 
hepatobiliary diseases such as AIH, PBC, PSC, and 
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Figure  3  endoscopic  retrograde  cholangiopancreatography  reveals  dilated 
intrahepatic ducts with the characteristic beading appearance suggestive of primary 
sclerosing cholangitis.
  autoimmune cholangitis (AIC) coexisting in an   individual.2 
They have a combination of hepatitic and cholestatic biochemi-
cal and histological features of AIH, PBC, PSC, and/or AIC, 
and usually show a progressive course toward liver cirrhosis 
and liver failure without adequate treatment.   AIH–PBC overlap 
syndrome has been reported in almost 10% of adults with AIH 
or PBC, whereas AIH–PSC overlap syndrome was found in 
6%–8% of children, adolescents, and young adults with AIH 
or PSC.3 A small amount of patients may also show a change 
from stable PBC to AIH, AIH to PBC, or AIH to PSC, as 
documented by single case reports and small case series. Single 
cases of AIH and AIC (AMA negative-PBC) overlap have also 
been reported. Transition from one autoimmune hepatopathy to 
another (eg, from PBC to AIH and from AIH to PSC) have also 
been reported.4 The overlap syndrome appears to be misused 
when characteristic features of an autoimmune hepatopathy 
are detected together with those of a second liver disease (eg, 
chronic hepatitis C). It is not clear whether these overlap syn-
dromes form separate groups or are only variants of the major 
autoimmune hepatic diseases.5 No standard diagnostic criteria 
for overlap syndromes has been achieved so far.6
This case showcases hepatic overlap syndrome with an 
uncommon combination of PBC–PSC associated with addi-
tional autoimmune disorder (rheumatoid arthritis). There has 
been no other case reported with co-existing PBC histology 
and PSC structural duct pattern with the background of 
rheumatoid arthritis. Only one other similar case has been 
reported with PSC histology and PBC specific antibodies. 
In our case patient, the AMA were negative with positive 
Figure  4  Magnetic  resonance  cholangiopancreatography  reveals  typical  beading 
appearance of dilated intrahepatic bile ducts characteristic of primary sclerosing 
cholangitis.
PBC histology suggesting the possibility of autoimmune 
cholangitis. However, immunofluorescence method was used 
instead of immunoblotting method which is more sensitive. 
A study of Japanese patients found the immunoblot was 
positive in nearly 30% of AMA negative patients by immu-
nofluorescence, suggesting that not all patients with AMA 
negative immunology are truly negative.7
In management of hepatic overlap syndromes there 
is no clear consensus on treatment. There are no specific 
management criteria for PBC–PSC that has been published 
thus far.8 In general, all of the overlap syndromes use one 
or more of the treatment options given below. It includes 
usage of UDCA if the combination includes PBC, PSC, or 
AIC. Studies reveal consistent evidence of improved liver 
biochemistries and improved survival. UDCA is widely used 
and has shown the ability to produce a reduction in need for 
liver transplantation. Immuno-suppressive therapies such as 
corticosteroids, especially prednisolone and azathioprine, are 
ideal options available. In steroid resistant cases of AIH-PBC, 
cyclosporine has been tried. Endoscopic stricture dilata-
tion and stenting also plays an important role in relieving 
the obstruction and helps in good biliary drainage. Liver 
transplantation is regarded as the treatment of choice in end 
stage liver disease secondary to overlap syndromes.
Periodic monitoring of liver function tests should be 
performed at three- to six-month intervals. This helps to 
detect the rare patients who go on to develop AIH on top International Journal of General Medicine
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of other combinations and also indicates whether UDCA is 
improving liver function. Thyroid status should be monitored 
annually. For patients with known cirrhosis with a Mayo risk 
score of more than 4.1, upper gastrointestinal endoscopy 
needs to be performed for assessment of varices every two 
to three years. Bone mineral density should be assessed 
every two to four years depending on baseline density and 
severity of cholestasis. Similarly, fat soluble vitamin levels 
should be monitored annually in patients with jaundice. 
Cross-sectional imaging usually with ultrasound and alpha-
fetoprotein levels to screen for hepatocellular cancer should 
be performed every 6–12 months in patients with cirrhosis 
and older men.
Conclusion
The exceptional rarity of this case scenario with overlap of 
PBC–PSC when compared with frequency of AIH–PBC 
and AIH–PSC overlap in patients with major autoimmune 
hepatobiliary diseases and the incidence is statistically less 
significant may lead to conclusion that this case would be a 
pure coexistence of PBC and PSC rather than a new overlap 
syndrome. UDCA is the only drug option beneficial in both 
PBC and PSC. Drugs such as chlorambucil, penicillamine, 
cyclosporine, corticosteroids, and azathioprine have been 
tested, but none have any benefits over UDCA. Until now 
there have been no effective studies that have given us 
any appropriate guidance for investigation, management, 
and   follow-up of the PBC–PSC patients. There is no 
clear evidence about risk of hepatobiliary tumors in these 
patients. For now treatment remains mainly symptomatic. 
Regular outpatient monitoring with liver-specific laboratory 
investigations and imaging is essential.
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